Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1
Authors:
- V. A. MarkovVMV. A. Markov
- D. V. DuplyakovD. V. Duplyakov
- S. L. KonstantinovSKS. L. Konstantinov
- G. V. KleinGKG. V. Klein
- С. Б. АксентьевСАС. Б. Аксентьев
- D. Yu. PlatonovDPD. Yu. Platonov
- E. V. VyshlovEVE. V. Vyshlov
- E. A. PonomarevEPE. A. Ponomarev
- R. M. RabinovichRRR. M. Rabinovich
- E. L. MakarovEME. L. Makarov
- E. V. KulibabaEKE. V. Kulibaba
- D. S. YunevichDYD. S. Yunevich
Open Access
- 6 December 2018
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 11,p. 110-116
Abstract
Aim. Evaluate the oneyear results and clinical outcomes of a multicenter randomized clinical trial FRIDOM1.Material and methods. The study FRIDOM1 was conducted in 11 clinical centers of the Russian Federation in the period 20142016. The study included 382 patients with acute STelevated myocardial infarction (STEMI), who were randomly divided into the Fortelyzin® and Metalyse®. Thrombolysis was accompanied by anticoagulant and dual antiplatelet therapy followed by percutaneous coronary intervention (PCI). Oneyear patient status, allcause mortality, including cardiovascular diseases (CVD), hospitalization, and oneyear survival were assessed by telephone contact.Results. The oneyear patient status was determined in 186 out of 191 (97,4%) in the Fortelyzin® group and in 185 out of 191 (96,9%) patients in the Metalyse® group. Oneyear allcause mortality was 5,9% and 6,5% in the Fortelyzin® and Metalyse® groups, respectively (p=0,83; OR 0,91; 95% CI — 0,421,98). Oneyear mortality from CVD in the Fortelyzin® group is 5,4%, in the Metalyse® group — 6,5% (p=0,67; OR 0,83; 95% CI — 0,371,83). Allcause mortality between 30 days and 1 year in the Fortelyzin® group was in 2,2% of patients, CVD — in 1,6%, in the group of Metalise® mortality was in 2,7% of patients (all — CVD). Oneyear survival was 94,1% and 93,5% in the Fortelyzin® and Metalyse® groups, respectively.Conclusion. The oneyear results of the FRIDOM1 study showed the efficacy and safety of a single bolus administration of Fortelyzin® as part of a pharmacoinvasive strategy for treating patients with STEMI, as well as clinical outcomes that are comparable with Metalyse®, including high survival rates and low CVD mortality.Keywords
This publication has 8 references indexed in Scilit:
- THE TASK FORCE FOR THE MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH ST-SEGMENT ELEVATION OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) 2017 ESC GUIDELINES FOR THEMANAGEMENT OF ACUTEMYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH ST-SEGMENT ELEVATIONRussian Journal of Cardiology, 2018
- RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTIONRational Pharmacotherapy in Cardiology, 2017
- THE PRINCIPLES OF ORGANIZATION OF AID AND PRE-HOSPITAL THROMBOLYSIS PATIENTS WITH ACUTE CORONARY SYNDROME IN THE CHUVASH REPUBLICEMERGENCY MEDICAL CARE, 2017
- THE RESULTS OF USE OF NEW NATIVE THROMBOLYTIC IN CLINICAL PRACTICERational Pharmacotherapy in Cardiology, 2016
- IN-PATIENT OUTCOMES OF PHARMACOINVASIVE REPERFUSION STRATEGY FOR ST ELEVATION MYOCARDIAL INFARCTIONRussian Journal of Cardiology, 2016
- CORONARY REPERFUSION IN ST ELEVATION MYOCARDIAL INFARCTION: PROBLEMS AND SOLUTIONSRussian Journal of Cardiology, 2015
- ST–Segment-Elevation Myocardial Infarction Patients Randomized to a Pharmaco-Invasive Strategy or Primary Percutaneous Coronary InterventionCirculation, 2014
- Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial InfarctionNew England Journal of Medicine, 2013